AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

The appendix is thought to play a role in all of this by producing inflammatory proteins that trigger the body to produce cascades of immune responses, according to a report of the study published ...

Avacopan treatment for antineutrophil cytoplasmic antibody–associated vasculitis demonstrated lower rates of adverse events, serious adverse events, white blood cell (WBC) count reductions ...

Appendectomy may be a useful addition to medical therapy for preventing relapse of ulcerative colitis among patients in remission. At 1 year, 36% of patients in the appendectomy group had a ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic inflammatory disease of the large intestine. While treatments for the disease ...

April 16 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) Patients with the chronic inflammatory bowel disease ulcerative colitis might reduce their risk of a ...

Vedolizumab as a first-line biologic in UC offers cost savings and clinical benefits, improving QALYs compared to TNF-α inhibitors. In CD, vedolizumab provides incremental benefits but incurs ...

It was an experience of a lifetime—she was hooked. So when Ricario was diagnosed with ulcerative colitis (UC) at the age of 40, one of her first worries was that her days as a world traveler ...